Hans van Houte, Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 5,368 shares at $19.81 ($106K) on 2025-01-30, disclosed to the SEC on 2025-01-30.
Open-market sale of $106k NRIX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.81 | 2,557 | $51K | 47.6% |
| 2 | $19.81 | 2,557 | $51K | 47.6% |
| 3 | $20.33 | 254 | $5K | 4.8% |
| Total | $19.83 avg | 5,368 | $106K | 100% |
| Filing → |
| NRIX | SELL | 2026-05-05 | $233K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $40K | — | Filing → |
| NRIX | SELL | 2026-01-30 | $122K | — | Filing → |